This is an open label, prospective, interventional cohort study conducted at a tertiary referral center. The primary end point is SVR12 in patients treated with sofosbuvir therapy for post liver transplant HCV recurrence. A total of 50 treatment experienced post liver transplant patients with histologic HCV recurrence received sofosbuvir and ribavirin ± peginterferon. Of those 50 patients, 34 (68%) were GT 4, 3 (6%) GT 2, 3 (6%) mixed GT 1&4 and 9 (18%) GT 1, and one patient had GT 3 (2%). All patients completed the follow up period. Mean Age was 60 years, the cohort included 32 males, and three patients had cirrhosis. Mean baseline HCV RNA was 8.3 log₁₀ IU/ml. The majority of patients had ≥ stage 2 fibrosis on liver biopsy. Thirty-one patients were treated with pegylated interferon plus ribavirin in addition to sofosbuvir for 12 weeks and the remaining were treated with sofosbuvir plus ribavirin only for 24 weeks. By week 4, seven patients had detectable HCV RNA. Of the 50 patients, 46 (92%) achieved SVR12 and 4 patients (8%) relapsed. Our results suggest that sofosbuvir based regimen can be utilized successfully to treat liver transplant patients with HCV recurrence. (Clinical trial number # RAC 2141038).

CITATION INFORMATION: Ajlan A, Aljedai A, Elsiesy H, Alkortas D, Alarieh R, Alhumodi W, Broring D, Alsebayel M, Aba Alkhail F. Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence. Am J Transplant. 2016;16 (suppl 3).

« Back to 2016 American Transplant Congress